ADP-TILIL7 / Adaptimmune - LARVOL DELTA

To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Inge Marie Svane | Trial completion date: Apr 2027 ➔ Apr 2028 | Trial primary completion date: Mar 2026 ➔ Mar 2027

Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Inge Marie Svane

Metastases • New P1 trial • Melanoma • Oncology • Solid Tumor

Next-Generation, Inducible IL-7-Expressing, Tumor-Infiltrating Lymphocytes by Lentiviral Vector Genetic Modification for Clinical Application (ASGCT 2022) - "However, T-cells are incapable of producing their own IL-7 and rely on secretion from surrounding stromal cells.11 We hypothesize that the introduction of an inducible IL-7 gene to TILs (next generation TIL; ADP-TILIL7) will improve their ability to engraft, proliferate, and survive, while maintaining diverse TIL specificity...Nat Rev Immunol. 2011;11(5):330."

Clinical • Melanoma • Oncology • Solid Tumor • IL7 • MAGEA4 • NFATC1

Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCT (GlobeNewswire) - "New next-gen SPEAR T-cells (ADP-A2M4N7X19) designed to enhance depth and durability of clinical response demonstrated enhanced proliferation, survival, and recruitment of immune cells in vitro....Engineered TILs (ADP-TILIL7) intended to improve clinical responses, produced levels of IL-7 shown to improve growth and survival in vitro....The Company is planning to initiate a Phase 1 trial with ADP-A2M4N7X19 in multiple solid tumors and a single-center, Phase 1 trial with ADP-TILIL7 for people with metastatic melanoma."

Preclinical • Melanoma • Oncology • Skin Cancer • Solid Tumor